2. Immunology/Inflammation
  3. PD-1/PD-L1
  4. Tislelizumab

Tislelizumab  (Synonyms: BGB-A317)

Cat. No.: HY-P99052 Purity: 98.10%
COA
SDS
Technical Support

Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma.

For research use only. We do not sell to patients.

CAS No. : 1858168-59-8

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Tislelizumab Featured Recommendations:

Tislelizumab Related Antibodies

Top Publications Citing Use of Products

    Tislelizumab purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 Jun 29;24(1):225.  [Abstract]

    Tislelizumab (50 µg/mL; 24 h). IFN-γ concentration in the supernatant of co-cultured cell lines was assessed by ELISA.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma[1][2][3].

    Isotype

    Human IgG4 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    PDCD1/PD-1/CD279
    In Vivo

    Tislelizumab (10 mg/kg; Intraperitoneal injection; Once a week; 4 weeks) has significant antitumor effect in the B16F10 melanoma mouse model[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: B16F10/GM-CSF tumor cells treated hPD-1 C57BL/6 transgenic mice[2]
    Dosage: 10 mg/kg
    Administration: Intraperitoneal injection (i.p.); once a week for 4 weeks.
    Result: Exerted remarkable antitumor efficacy, resulting in approximate 86.7% tumor growth inhibition.
    Clinical Trial
    Gene ID

    5133  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    145 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Tislelizumab]
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG4 kappa
    Biological Activity
    • Flow cytometry analysis of PD-1 overexpression Jurkat cells labelling PD-1 with Tislelizumab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
    Purity & Documentation

    Purity: 98.10%

    SDS (251 KB)

    COA (232 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Tislelizumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Tislelizumab1858168-59-8BGB-A317PD-1/PD-L1PD-1/Programmed death-ligand 1monoclonal antibodyPD-1 receptorminimizes Fcγ receptor binding on macrophagesadvanced squamous non-small-cell lung cancerInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Tislelizumab
    Cat. No.:
    HY-P99052
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.